Younossi, ZM, Ratziu, V, Loomba, R, Rinella, M, Anstee, QM, Goodman, Z, Bedossa, P, Geier, A, Beckebaum, S, Newsome, PN
, Sheridan, D, Sheikh, MY, Trotter, J, Knapple, W, Lawitz, E, Abdelmalek, MF, Kowdley, KV, Montano-Loza, AJ, Boursier, J, Mathurin, P, Bugianesi, E, Mazzella, G, Olveira, A, Cortez-Pinto, H, Graupera, I, Orr, D, Gluud, LL, Dufour, JF, Shapiro, D, Campagna, J, Zaru, L, MacConell, L, Shringarpure, R, Harrison, S, Sanyal, AJ, Abdelmalek, MF, Abrams, G, Aguilar, H, Ahmed, A, Aigner, E, Aithal, G, Ala, A, Alazawi, W, Albillos, A, Allison, M, Al-Shamma, S, Andrade, R, Andreone, P, Angelico, M, Ankoma-Sey, V, Anstee, QM, Anty, R, Araya, V, Arenas, RJI, Arkkila, P, Arora, M, Asselah, T, Au, J, Ayonrinde, O, Bailey, RJ, Balakrishnan, M, Bambha, K, Bansal, M, Barritt, S, Bate, J, Beato, J, Beckebaum, S, Behari, J, Bellot, P, Ben, AZ, Bennett, M, Berenguer, M, Beretta-Piccoli, BT, Berg, T, Bonacini, M, Bonet, L, Borg, B, Bourliere, M, Boursier, J, Bowman, W, Bradley, D, Brankovic, M, Braun, M, Bronowicki, J-P, Bruno, S, Bugianesi, E, Cai, C & Calleja, PJL 2019, '
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial',
The Lancet, vol. 0, no. 0.
https://doi.org/10.1016/s0140-6736(19)33041-7